Actinium Pharmaceuticals Further Strengthens Team Adding an Accomplished Finance and Corporate Development Professional

Press Releases  |

Steve O'Loughlin Joins Actinium Team as Senior Director of Finance and Corporate Development


NEW YORK, NY--(October 13, 2015) - Actinium Pharmaceuticals, Inc. (ATNM) ("Actinium" or "the Company") is a biopharmaceutical Company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers. Actinium announced today the appointment of Steve O'Loughlin to the position of Senior Director of Finance and Corporate Development. In his new role, Steve will be a member of the leadership team and will report to Sandesh Seth, Executive Chairman of Actinium. Steve will be responsible for developing and executing the Company's investor relations and corporate communications programs, interacting with the investment community as well as providing high-level financial support for Actinium's strategic growth initiatives.

"Actinium is pleased to welcome Steve to team," said Sandesh Seth, Executive Chairman of Actinium. "As we continue to progress our Iomab-B and Actimab-A programs in the clinic we look forward to having Steve on board to communicate our value proposition and developments to the investment community."

"I am very excited to join the Actinium team and eager to assume my responsibilities," said Mr. O'Loughlin. "Actinium continues to progress Iomab-B and Actimab-A through the clinic in indications with significant unmet medical needs while expanding its pipeline and I look forward to communicating and interacting with the investment community on our developments. With Iomab-B poised to enter a pivotal Phase 3 trial, Actimab-A moving towards a Phase 2 trial and an ever strengthening team it is an honor to join Actinium at such a momentous time for the Company."

Steve joins Actinium with almost a decade of life sciences industry experience gained from previous positions in investment banking and publicly traded life sciences companies. Most recently, Steve held the position of Vice President, Corporate Finance and Development and was a corporate officer at Protea Biosciences, Inc., a publicly traded life sciences tools company. At Protea, Steve worked with the executive management team to raise capital, execute strategic partnerships such as the Company's collaboration and co-marketing agreement with InSphero AG and represented the Company to the investment community. Previously, Steve held corporate development positions with Caliber I.D., a publicly traded diagnostics company, where he helped commercialize Caliber I.D.'s FDA cleared VivaScope®diagnostic device, supported academic research collaborations and supported the executive management team in the execution of private placements and the Company's IPO. Steve previously worked in investment banking at Jesup & Lamont where he focused on the biotechnology and life sciences industries. Steve has a B.S. in Business Administration with a concentration in finance from Ramapo College of New Jersey and is pursuing his CFA designation.

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc. ( is a New York-based biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers. Actinium's targeted radiotherapy products are based on its proprietary delivery platform for the therapeutic utilization of alpha-emitting actinium-225 and bismuth-213 and certain beta emitting radiopharmaceuticals in conjunction with monoclonal antibodies. The Company's lead radiopharmaceutical product candidate Iomab-B is designed to be used, upon approval, in preparing patients for hematopoietic stem cell transplant, commonly referred to as bone marrow transplant. The Company plans to conduct a single, pivotal, multicenter Phase 3 clinical study of Iomab-B in refractory and relapsed AML patients over the age of 55 with a primary endpoint of durable complete remission. The Company's second product candidate, Actimab-A, is continuing its clinical development in a Phase 1/2 trial for newly diagnosed AML patients over the age of 60 in a single-arm multicenter trial.

Forward-Looking Statement for Actinium Pharmaceuticals, Inc.

This news release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause actual results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, or financial performance. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Actinium Pharmaceuticals undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.


Contact Information



Steve O'Loughlin
Senior Director, Finance and Corporate Development
Actinium Pharmaceuticals, Inc.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to:


Symbol Name Price Change % Volume
ATNM Actinium Pharmaceuticals Inc. (Delaware) 0.46 -0.02 -3.75 925,294


Emerging Growth

IMV Inc.

Immunovaccine Inc is clinical stage biopharmaceutical company. The Company develops products based on its proprietary vaccine enhancement platform in T cell activating therapies for cancer.